Allen & Overy advises Exscientia on its oncology joint venture with GT Apeiron Therapeutics
Related people
Headlines in this article
Related news and insights
Publications: 04 April 2024
Integrating Sustainability: Luxembourg's Legal Advancements with the CSRD
Blog Post: 03 April 2024
European Commission opens unprecedented abuse of dominance probe in animal medicines sector
Blog Post: 28 March 2024
News: 27 March 2024
Allen & Overy advises on the sale of majority stake in GasNet
Allen & Overy has advised Exscientia on its strategic research and development collaboration agreement with GT Apeiron Therapeutics (GTA). The collaboration will leverage Exscientia’s AI-driven drug discovery platform to accelerate the discovery of multiple small molecule therapeutic drug candidates designed to selectively treat aberrant cell cycle driven cancers and build a pipeline of CDK novel therapies.
Expanding on an existing CDK7 drug discovery partnership, the collaboration includes additional CDK targeting drugs. The potent, highly selective, non-covalent CDK7 compounds have demonstrated consistent tumour responses in xenograft models as well as exceptional pharmacokinetics. In addition, using live primary tissue samples from ovarian cancer patients, the CDK7 inhibitors showed both enhanced tumour cell cytotoxicity as well as selectivity over immune cells in the same microenvironment.
All pipeline products will be equally owned and Exscientia holds an equity stake in GTA.
The A&O team was led by London partner Jim Ford, assisted by London associate Megan McMellon.